Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer

G. Minuti, F. Cappuzzo, R. Duchnowska, J. Jassem, A. Fabi, T. Obrien, A. D. Mendoza, L. Landi, W. Biernat, B. Czartoryska-Arukowicz, T. Jankowski, D. Zuziak, J. Zok, B. Szostakiewicz, M. Foszczyska-Koda, A. Tempiska-Szaach, E. Rossi, M. Varella-Garcia

Research output: Contribution to journalArticlepeer-review

Abstract

Background:To investigate whether copy number gain of MET or hepatocyte growth factor (HGF) affect trastuzumab sensitivity in HER2-positive metastatic breast cancer (MBC).Methods:We analysed 130 HER2-positive MBC treated with trastuzumab-based therapy. MET and HGF gene copy numbers (GCN) were assessed by fluorescence in situ hybridisation (FISH) in primary breast cancer samples. Receiver operating characteristic analysis was applied to find the best cutoff point for both MET and HGF GCN.Results:MET FISH-positive cases (N=36, mean ≥3.72) had a significantly higher trastuzumab failure rate (44.4% vs 16.0%; P=0.001) and a significantly shorter time to progression (5.7 vs 9.9 months; HR 1.74; P=0.006) than MET FISH-negative cases (N=94, mean

Original languageEnglish
Pages (from-to)793-799
Number of pages7
JournalBritish Journal of Cancer
Volume107
Issue number5
DOIs
Publication statusPublished - Aug 21 2012

Keywords

  • breast cancer
  • HER2-positive
  • HGF
  • MET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.

Cite this